Astex Therapeutics Ltd of Cambridge, UK, has concluded a drug discovery deal with GlaxoSmithKline giving GSK access to its fragment chemistry platform. The deal includes upfront and equity investments valued at £20 million.
Astex Therapeutics Ltd of Cambridge, UK, has concluded a drug discovery deal with GlaxoSmithKline giving GSK access to its fragment chemistry platform. The deal includes upfront and equity investments valued at £20 million.